A clinical formulation indicated for Hormone Therapy. This medicine supports the balance of electrolytes and fluid levels by managing vasopressin activity in the body.
Intended to manage fluid overload by addressing electrolyte imbalances to alleviate low blood sodium and support kidney health in polycystic disease patients effectively.
Mechanism of Action
Tolvaptan blocks the action of vasopressin in the kidneys. This prevents the body from retaining too much water, allowing the kidneys to excrete excess fluid without losing essential electrolytes like sodium.
Route of Administration
Oral
Onset Time
2–4 hours
Duration
24 hours
Contraindications
Need to increase sodium rapidly, Inability to sense thirst, Anuria, Severe liver disease, Strong CYP3A inhibitors
Severe Adverse Events
Severe liver injury, Osmotic demyelination syndrome, Dehydration, Gastrointestinal bleeding, Severe allergic reactions
Information for Tolvaptan is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
